The first trial assessing Atezolizumab/Bevacizumab with TACE or local ablation for treatment of hepatocellular carcinoma
Study design
The diagram above is a schematic representation of the DEMAND study design, a randomised, two-arm phase II study on the efficacy of atezolizumaband bevacizumab (Atezo/Bev) followed by on-demand selective trans-arterial chemoembolisation (sdTACE) on detection of disease progression (PD), or of initial synchronoustreatment with TACE and Atezo/Bev on 24 months survival rate in the treatment of unresectable hepatocellular carcinoma patients. The use of localablation (RFA or MWA) is allowed for lesions which cannot be targeted sufficiently selectively by TACE (from Gut October 2020 Vol 69 No 10 )
Participating sites in Germany
Actively recruiting
AACHEN
Uniklinik RWTH
CHEMNITZ
Klinikum Chemnitz gGmbH
ESSEN
Universitätsklinikum
ESSLINGEN
Klinikum Esslingen
HAMBURG
Universitätsklinikum Hamburg-Eppendorf
JENA
Universitätsklinikum Jena
KÖLN
Uniklinik Köln
MAGDEBURG
Universitätsklinikum Magdeburg
MÜNCHEN
Klinikum Grosshadern
MÜNCHEN
Klinikum Rechts der Isar
NÜRNBERG
Paracelsus Universitätsklinik
REGENSBURG
Universitätsklinikum Regensburg
TÜBINGEN
Universitätsklinikum Tübingen
WÜRZBURG
Universitätsklinikum Würzburg
Sponsor
